Boehringer Drug Combination Showed Response at 12 Weeks in Study

Nov. 7 (Bloomberg) -- Boehringer Ingelheim GmbH said 76 percent of patients taking an interferon-free combination of two experimental drugs with ribavirin had a virological response after 12 weeks in a mid-stage study.

The data from an interim analysis of the Sound-C2 trial, which tested drugs BI201335 and BI207127, was presented today at the American Association for the Study of Liver Disease meeting in San Francisco.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net